1. Antiangiogenesis Mediates Cisplatin-Induced Peripheral Neuropathy
- Author
-
Carole Amant, Masaaki, David H. Weinberg, Alberto Weber, Andrea Wecker, Kenneth M. Rosen, Eleftheria Panagiotou, Allan H. Ropper, Dirk H. Walter, Young Sup Yoon, Lester S. Adelman, Ferdinand H. Bahlmann, Toshinori Murayama, Marcy Silver, Peter Schratzberger, Costanza Emanueli, Anne B. Tietz, Kilian Rittig, Douglas W. Losordo, Jeffrey M. Isner, and Rudolf Kirchmair
- Subjects
Male ,Vascular Endothelial Growth Factor A ,Umbilical Veins ,Endothelium ,Angiogenesis ,Genetic enhancement ,medicine.medical_treatment ,Vasa Nervorum ,Angiogenesis Inhibitors ,Apoptosis ,Rats, Sprague-Dawley ,chemistry.chemical_compound ,Neoplasms ,Physiology (medical) ,Vasa nervorum ,medicine ,Animals ,Humans ,Cisplatin ,business.industry ,Growth factor ,Peripheral Nervous System Diseases ,Genetic Therapy ,medicine.disease ,Rats ,Tumor Burden ,Vascular endothelial growth factor ,medicine.anatomical_structure ,Peripheral neuropathy ,chemistry ,Immunology ,Cancer research ,Endothelium, Vascular ,Cardiology and Cardiovascular Medicine ,business ,medicine.drug - Abstract
Background— Toxic neuropathies induced by cisplatin and other chemotherapeutic agents are important clinical problems because of their high incidence, their lack of effective treatment, and the fact that neuropathy represents a dose-limiting factor for these therapies. The pathogenic basis for toxic neuropathies induced by chemotherapeutic agents has not been completely elucidated. Methods and Results— We investigated the hypothesis that experimental toxic neuropathy results from an antiangiogenic effect of these drugs, resulting in destruction of the vasa nervorum, and accordingly that the neuropathy could be prevented or reversed by locally administered VEGF gene transfer without augmenting tumor growth. In an animal model of cisplatin-induced neuropathy, nerve blood flow was markedly attenuated, and there was a profound reduction in the number of vasa nervorum associated with marked endothelial cell apoptosis, resulting in a severe peripheral neuropathy with focal axonal degeneration characteristic of ischemic neuropathy. After intramuscular gene transfer of naked plasmid DNA encoding VEGF-1 in animals with an established neuropathy, vascularity and blood flow returned to levels similar to those of control rats, peripheral nerve function was restored, and histological nerve architecture was normalized. Gene therapy administered in parallel with cisplatin chemotherapy completely attenuated endothelial cell apoptosis and inhibited destruction of nerve vasculature, deterioration of nerve function, and axonal degeneration. In a rat tumor model, VEGF gene transfer administered locally did not alter tumor growth or vascularity. Conclusions— These findings implicate microvascular damage as the basis for toxic neuropathy induced by cisplatin and suggest that local angiogenic gene therapy may constitute a novel prevention or treatment for this disorder without augmenting tumor growth or vascularization.
- Published
- 2005
- Full Text
- View/download PDF